FindTrial
Sign In

Safety and efficacy profile of SGLT2 inhibitors on contrast-related acute kidney injury in patients with type 2 diabetes: a multicenter, prospective cohort study

Safety and efficacy profile of SGLT2 inhibitors on contrast-related acute kidney injury in patients with type 2 diabetes: a multicenter, prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039665
Enrollment
Unknown
Registered
2020-11-05
Start date
2020-12-31
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-Associated Acute Kidney Injury.

Interventions

SGLT2i group:Nil
no SGLT2i group:Nil

Sponsors

The Eighth Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Definite diagnosis of type 2 diabetes, unlimited medical history, aged >= 18 years; (2) eGFR >= 30ml/(min·1.73 m2) (CKD-EPI equation); (3) Intravascular angiography is planned; (4) Sign the informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: (1) End-stage renal disease; (2) Maintenance hemodialysis or peritoneal dialysis; (3) Allergy to iodine contrast agent; (4) Repeated use of contrast agent within a short period of time (48-72h); (5) Pregnancy and lactation; (6) Rheumatic immune diseases; (7) Malignant tumors; (8) Kidney transplantation.

Design outcomes

Primary

MeasureTime frame
serum Scr;Hematocrit;—

Secondary

MeasureTime frame
serum Cysc;—

Countries

China

Contacts

Public ContactGuifu Wu

The Eighth Affiliated Hospital of Sun Yat-Sen University

wuguifu@mail.sysu.edu.cn+86 15989893111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026